Changes in the cannabinoid receptor binding, G protein coupling, and cyclic AMP cascade in the CNS of rats tolerant to and dependent on the synthetic cannabinoid compound CP55,940

被引:65
作者
Rubino, T [1 ]
Viganò, D [1 ]
Massi, P [1 ]
Parolaro, D [1 ]
机构
[1] Univ Milan, Dept Pharmacol Chemotherapy & Toxicol, Milan, Italy
关键词
CP55,940; brain; cannabinoid receptor; G proteins; cyclic AMP cascade;
D O I
10.1046/j.1471-4159.2000.0752080.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chronic exposure to CP55,940 produced a significant down-regulation of cannabinoid receptors in the striatum, cortex, hippocampus, and cerebellum of rat brain. At 24 h after SR141716-precipitated withdrawal, we observed a tendency to return to basal levels in the striatum and cortex, whereas the specific binding remained lower in the hippocampus and cerebellum. When we surveyed cannabinoid receptor-activated G proteins, in chronic CP55,940-treated rats the guanosine 5'-O-(3-[S-35]thiotriphosphate) ([S-35]GTP gamma S) binding assay revealed a decrease of activated G proteins in the striatum, cortex, and hippocampus, whereas no significant changes were seen in the cerebellum. At 24 h after the SR141716-precipitated withdrawal, [S-35]GTP gamma S binding increased compared with that of rats chronically exposed to CP55,940, attaining the control level except for cerebellum, where we observed a trend to overcome the control amounts. Concerning the cyclic AMP (cAMP) cascade, which represents the major intracellular signaling pathway activated by cannabinoid receptors, in the cerebral areas from rats chronically exposed to CP55,940 we found alteration in neither cAMP levels nor protein kinase A activity. In the brain regions taken from CP55,940-withdrawn rats, we only observed a significant up-regulation in the cerebellum. Our findings suggest that receptor desensitization and down-regulation are strictly involved in the development of cannabinoid tolerance, whereas alterations in the cAMP cascade in the cerebellum could be relevant in the mediation of the motor component of cannabinoid abstinence.
引用
收藏
页码:2080 / 2086
页数:7
相关论文
共 31 条
[1]  
Aceto MD, 1996, J PHARMACOL EXP THER, V278, P1290
[2]   A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1 - Evidence for a new model of receptor/ligand interactions [J].
Bouaboula, M ;
Perrachon, S ;
Milligan, L ;
Canat, X ;
RinaldiCarmona, M ;
Portier, M ;
Barth, F ;
Calandra, B ;
Pecceu, F ;
Lupker, J ;
Maffrand, JP ;
LeFur, G ;
Casellas, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (35) :22330-22339
[3]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[4]   Chronic Δ9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain [J].
Breivogel, CS ;
Childers, SR ;
Deadwyler, SA ;
Hampson, RE ;
Vogt, LJ ;
Sim-Selley, LJ .
JOURNAL OF NEUROCHEMISTRY, 1999, 73 (06) :2447-2459
[5]  
Breivogel CS, 1997, J PHARMACOL EXP THER, V282, P1632
[6]   Delta(9)-tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain [J].
Burkey, TH ;
Quock, RM ;
Consroe, P ;
Roeske, WR ;
Yamamura, HI .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 323 (2-3) :R3-R4
[7]   Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain [J].
Burkey, TH ;
Quock, RM ;
Consroe, P ;
Ehlert, FJ ;
Hosohata, Y ;
Roeske, WR ;
Yamamura, HI .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 336 (2-3) :295-298
[8]   Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor [J].
Calandra, B ;
Portier, M ;
Kernéis, A ;
Delpech, M ;
Carillon, C ;
Le Fur, G ;
Ferrara, P ;
Shire, D .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 374 (03) :445-455
[9]  
Cook SA, 1998, J PHARMACOL EXP THER, V285, P1150
[10]   Comparison of novel cannabinoid partial agonists and SR141716A in the guinea-pig small intestine [J].
Coutts, AA ;
Brewster, N ;
Ingram, T ;
Razdan, RK ;
Pertwee, RG .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 129 (04) :645-652